Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
MD 
Mednax Inc (MD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: MD (3-star) is a REGULAR-BUY. BUY since 81 days. Simulated Profits (42.71%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.67
1 Year Target Price $22.67
| 3 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.09% | Avg. Invested days 44 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.93B USD | Price to earnings Ratio 11.58 | 1Y Target Price 22.67 |
Price to earnings Ratio 11.58 | 1Y Target Price 22.67 | ||
Volume (30-day avg) 8 | Beta 0.77 | 52 Weeks Range 11.84 - 24.99 | Updated Date 12/5/2025 |
52 Weeks Range 11.84 - 24.99 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.44% | Operating Margin (TTM) 15.02% |
Management Effectiveness
Return on Assets (TTM) 6.86% | Return on Equity (TTM) 19.98% |
Valuation
Trailing PE 11.58 | Forward PE 9.33 | Enterprise Value 2093372933 | Price to Sales(TTM) 1 |
Enterprise Value 2093372933 | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 1.09 | Enterprise Value to EBITDA 7.92 | Shares Outstanding 85877386 | Shares Floating 83049727 |
Shares Outstanding 85877386 | Shares Floating 83049727 | ||
Percent Insiders 2.13 | Percent Institutions 98.63 |
Upturn AI SWOT
Mednax Inc
Company Overview
History and Background
Mednax Inc, now known as Pediatrix Medical Group (MD), was founded in 1979. Initially focused on neonatal physician services, it expanded through acquisitions to include other pediatric subspecialties and maternal-fetal medicine. Over time, it divested some non-core assets to focus on its core business.
Core Business Areas
- Pediatrix and Obstetrix Medical Groups: Provide physician services, including newborn, maternal-fetal, and pediatric subspecialty care. This forms the core of their business, offering clinical services to hospitals and other healthcare facilities.
Leadership and Structure
The company is led by a Chief Executive Officer and has a board of directors. Its operational structure is organized around its core medical service lines, with regional and local leadership managing physician groups and hospital partnerships.
Top Products and Market Share
Key Offerings
- Newborn Physician Services: Provides neonatology and newborn intensive care services to hospitals. The market is fragmented, with Pediatrix being one of the larger providers. Competitors include Envision Healthcare and various regional physician groups. Revenue from this segment is significant as it is a core service.
- Maternal-Fetal Medicine: Offers specialized care for high-risk pregnancies. This service line benefits from demographic trends and increasing complexity in maternal care. Competitors include regional providers and academic medical centers. Revenue forms a material portion of the company's topline revenue.
Market Dynamics
Industry Overview
The market for physician services is characterized by increasing demand due to population growth, aging demographics, and advancements in medical technology. There is also pressure from payers to control costs and improve outcomes.
Positioning
Pediatrix holds a leading position in newborn and maternal-fetal medical care, with a national presence and a focus on high-quality, specialized services. Its competitive advantages include its scale, expertise, and established relationships with hospitals.
Total Addressable Market (TAM)
The total addressable market for neonatal and maternal-fetal physician services in the US is estimated to be in the billions of dollars annually. Pediatrix is positioned to capture a substantial portion through its national footprint and specialized offerings.
Upturn SWOT Analysis
Strengths
- National Scale
- Specialized Expertise
- Established Hospital Relationships
- Comprehensive Service Offerings
Weaknesses
- High debt levels
- Dependence on reimbursements
- Potential for physician turnover
- Reputational risk related to medical outcomes
Opportunities
- Expanding into underserved markets
- Developing value-based care models
- Leveraging technology to improve efficiency
- Acquiring smaller physician groups
Threats
- Changes in healthcare regulations
- Increased competition from other providers
- Downward pressure on reimbursement rates
- Economic downturn affecting hospital budgets
Competitors and Market Share
Key Competitors
- EHC
- USPH
- AMN
Competitive Landscape
Pediatrix competes on its scale, expertise, and established relationships. Its disadvantages compared to smaller competitors include higher overhead and potential for slower decision-making. Compared to larger diversified healthcare companies, Pediatrix is more specialized.
Major Acquisitions
Obstetrix Medical Group of Phoenix
- Year: 1997
- Acquisition Price (USD millions):
- Strategic Rationale: Expanded the geographic presence and service offerings in Maternal-Fetal Medicine.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by acquisitions and organic expansion of service offerings. Recent years have focused on operational efficiency and strategic divestitures.
Future Projections: Future growth depends on factors such as healthcare spending trends, regulatory changes, and the company's ability to execute its strategic plan. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include cost-cutting measures, focusing on core service lines, and expanding into new geographies.
Summary
Pediatrix Medical Group, now MD, holds a significant position in neonatal and maternal-fetal care, benefiting from its national scale and specialized expertise. However, it faces challenges from industry competition and regulatory changes. Focusing on operational efficiency and strategic expansion will be critical for future growth. High debt also impacts the future growth and shareholder confidence.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mednax Inc
Exchange NYSE | Headquaters Sunrise, FL, United States | ||
IPO Launch date 1995-09-19 | CEO & Executive Chairman Mr. Mark S. Ordan | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 4120 | Website https://www.pediatrix.com |
Full time employees 4120 | Website https://www.pediatrix.com | ||
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal medicine nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and other newborn and pediatric care, as well as newborn hearing screening, and support services in hospitals, pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.